Form 4: Celldex Therapeutics Director Granted Stock Options

Celldex Therapeutics reports a stock option grant to Director Denice Torres, with an exercise price of $34.09.

Summary

• Director Denice Torres was granted 26,000 non-qualified stock options by Celldex Therapeutics, Inc.
• The options have an exercise price of $34.09 per share.
• These options were granted under the company's 2021 Omnibus Equity Incentive Plan.
• The earliest transaction date associated with this filing is June 25, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard stock option grant to a director, which is a common practice and does not inherently signal positive or negative performance.

Positives

• Grant of stock options to a director can align management incentives with shareholder value.
• The grant indicates continued investment in key personnel and leadership.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance. It solely reports a stock option grant.

Industry Context

StockSavvy.ai notes that equity incentive plans are a common tool in the biotechnology and pharmaceutical sectors to attract and retain talent, especially for companies focused on research and development where long-term value creation is paramount.

Stakeholder Impact

• Shareholders: The grant of options could lead to future dilution if exercised, but also aligns director interests with long-term company performance.

Next Steps

• Denice Torres may exercise the stock options between June 25, 2027, and June 25, 2036, subject to the terms of the 2021 Omnibus Equity Incentive Plan.

Key Dates

Keywords

stock options, equity incentive plan, director compensation, Celldex Therapeutics, CLDX, SEC Form 4